scholarly journals Thickness of the retinal photoreceptor outer segment layer in healthy volunteers and in patients with diabetes mellitus without retinopathy, diabetic retinopathy, or diabetic macular edema

2017 ◽  
Vol 31 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Abdullah Ozkaya ◽  
Zeynep Alkin ◽  
Yalcin Karakucuk ◽  
Gonul Karatas ◽  
Korhan Fazil ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Healthy Volunteers ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Outer Segment ◽  
Photoreceptor Outer Segment ◽  
Retinal Photoreceptor ◽  
Patients With Diabetes

scholarly journals RELATIONSHIP BETWEEN PHOTORECEPTOR OUTER SEGMENT LENGTH AND VISUAL ACUITY IN DIABETIC MACULAR EDEMA

Retina ◽  
2010 ◽  
Vol 30 (1) ◽  
pp. 63-70 ◽  
Author(s):  
FARZIN FOROOGHIAN ◽  
PAUL F. STETSON ◽  
SCOTT A. MEYER ◽  
EMILY Y. CHEW ◽  
WAI T. WONG ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Outer Segment ◽  
Segment Length ◽  
Photoreceptor Outer Segment

scholarly journals Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Jorge S. Andrade Romo ◽  
Giselle Lynch ◽  
Kevin Liu ◽  
Daniel Kim ◽  
Michael Jansen ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Therapeutic Response ◽  
Diagnostic Methods ◽  
Fundus Photography ◽  
Additional Information ◽  
Structural Improvement ◽  
Anti Vegf ◽  
Patients With Diabetes

Anti-VEGF treatment of diabetic macular edema (DME) complicating diabetic retinopathy (DR) has greatly improved structural and visual outcomes for patients with diabetes mellitus. However, up to 50% of patients are either nonresponsive or refractory to anti-VEGF treatment (no improvement in BCVA or central macular thickness (CMT)). It is believed that factors such as mitochondrial structural and functional damage, due to oxidative stress, are partially responsible for this lack of improvement. Flavoprotein fluorescence (FPF) has been shown to be a sensitive marker of mitochondrial function and has been found to correlate with the degree of diabetic retinopathy. FPF may also provide additional information regarding therapeutic response of patients receiving anti-VEGF treatment for DME. Eight patients with DR and DME with clinically significant DME (CSDME) who underwent anti-VEGF (bevacizumab) treatment were imaged before injection and at follow-up visit using FPF in addition to standard color fundus photography and OCT CMT. A strong correlation r=0.98 (p=0.000015) between the FPF decrease and the BCVA improvement was observed; BCVA improved as FPF values decreased. Notably, in the same patients, the correlation between OCT CMT decrease and BCVA improvement (r=0.688) was not found to be significant (p=0.13). These findings suggest that FPF can detect improvement in metabolic function preceding structural improvement and even with small changes in edema. Additionally, FPF may be supplementary to current diagnostic methods for earlier detection of therapeutic response to anti-VEGF treatment in patients with DME.

scholarly journals Quantitative Assessment of Outer Retinal Layer and Photoreceptor Outer Segment Layer and Their Relation to Visual Acuity in Diabetic Macular Edema

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Ahmed Hosni Abd Elhamid
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Quantitative Assessment ◽  
Outer Segment ◽  
Retinal Layer ◽  
Moderate Correlation ◽  
Weak Correlation ◽  
Photoreceptor Outer Segment ◽  
Corrected Visual Acuity

Purpose. To compare outer retinal layer (ORL) thickness and photoreceptor outer segment (PROS) length between normal eyes and eyes with diabetic macular edema (DME), and also, to study the correlation between central macular thicknesses (CMT), ORL, and PROS length with best corrected visual acuity (BCVA) in DME. Methods. 80 eyes were included in the study; they were divided into two groups, group Ι (40 normal eyes) and group ΙΙ (40 eyes) with DME. Complete ophthalmic examination and OCT were done for all eyes. Comparison between ORL and PROS was done between both groups; also, correlation between ORL thickness, PROS length, and CMT with BCVA in group ΙΙ was studied. Results. CMT was greater in group ΙΙ than group Ι (392.70 ± 62.91 and 265.73 ± 17.17, respectively) (SS, p<0.001). ORL thickness was statistically significantly greater in group Ι than group ΙΙ (104.80 ± 4.94, 93.68 ± 6.34, p<0.001). Regarding PROS length, it was statistically significantly greater in group Ι than group ΙΙ (31.38 ± 3.4 and 26.65 ± 3.39, respectively, p<0.001). There was moderate correlation between BCVA and ORL thickness (r = −0.440, p=0.004) and strong correlation between BCVA and PROS length in group ΙΙ (r = − 0.690, p<0.001), while there was weak correlation between BCVA and CMT (r = 0.198, p=0.220). Conclusion. Both ORL thickness and PROS length were greater in healthy normal eyes than eyes with DME. BCVA was correlated better with PROS length and ORL thickness than CMT.

scholarly journals Variability of diabetic macular edema in correlation with hypertension retinopathy in patients with diabetes mellitus and essential hypertension

2019 ◽  
Vol 63 (4) ◽  
pp. 327-338 ◽  
Author(s):  
Daniela Stana ◽  
Vasile Potop ◽  
Sînziana Luminiţa Istrate ◽  
Cecilia Eniceicu ◽  
Ana Raluca Mihalcea ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Essential Hypertension ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Patients With Diabetes

Effectiveness of intravitral anti-vegf therapy application in treatment of diabetic macular edema

2021 ◽  
pp. 9-11
Author(s):  
M.M. Bikbov ◽  
◽  
K.I. Kudoyarova ◽  
R.M. Zainullin ◽  
T.R. Gilmansin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Randomized Clinical Trials ◽  
Normal Values ◽  
Anti Vegf ◽  
Intravitreal Aflibercept ◽  
Patients With Diabetes

Purpose. To study the effectiveness of the use of intravitreal anti-VEGF therapy for macular edema in patients with diabetes. Material and methods. The study involved 42 patients (42 eyes) with macular edema, against the background of compensated type 2 diabetes mellitus. All patients received 5 loading doses of aflibercept with an interval of 1 month. Monthly optical coherence tomography of the macular region of the operated eye was performed, and visual acuity and intraocular pressure were determined. Results. After 5 intravitreal aflibercept injections, the thickness of the retina reached normal values and averaged 183.8 ± 19.9, IOP was within 15.0 mm Hg. Art. in all cases. The percentage of resistance to aflibercept therapy was 14.3%, which is also consistent with the results of randomized clinical trials. Conclusion. Intravitreal administration of aflibercept has been shown to be highly effective in the treatment of diabetic macular edema and allowed to increase visual acuity to 0.5 ± 0.1 after 5 intravitreal injections in 85.7% of patients. Key words: diabetic retinopathy, macular edema, anti-VEGF therapy.

scholarly journals Systemic and local diseases associated with the development of diabetic macular edema among Japanese patients with diabetes mellitus

2020 ◽  
Author(s):  
Atuki Kume ◽  
Kenji Kashiwagi
Keyword(s):  
Diabetes Mellitus ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Vision Loss ◽  
Univariate Analysis ◽  
Japanese Patients ◽  
Logistic Analysis ◽  
Patients With Diabetes ◽  
Severe Vision Loss ◽  
One Year

Abstract Background Diabetic macular edema (DME) causes severe vision loss among patients with diabetes mellitus (DM). We aimed to investigate systemic and local diseases associated with the development of DME among a Japanese population. Methods A total of 3.11 million Japanese subjects who were registered in the database of the Japan Medical Data Center from 2005 to 2014 were analyzed. Subjects with DM were defined as individuals who had been prescribed any therapeutic medications for DM, and associated diseases were analyzed. The periods analyzed were one year before the development of DME among patients with DME and one year before the last visit to an ophthalmic clinic among patients without DME. Results A total of 17,403 patients with DM satisfied the inclusion and exclusion criteria, and 420 patients developed DME. Univariate analysis revealed significant associations between 55 diseases, including 39 systemic and 16 local diseases, and DME development. The logistic analysis identified 21 systemic diseases and 10 local diseases as significant factors associated with DME development. Various types of systemic and local diseases were associated with DME development. Conclusion Subjects with DM who present these risk factors must be carefully monitored to prevent visual impairment.

Sign in / Sign up

Export Citation Format

Share Document